Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: The view of an eyewitness

被引:69
|
作者
Hornykiewicz, Oleh [1 ]
机构
[1] Med Univ Vienna, Ctr Brain Res, Vienna, Austria
关键词
dopamine; striatum; Parkinson's disease; nigrostriatal dopamine pathway;
D O I
10.1159/000113678
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The article recapitulates some of the historical facts that led up to the recognition of dopamine (DA) as a biologically active substance in the brain and its crucial role in Parkinson's disease (PD). Three events to which the writer has been an eyewitness are specially highlighted and placed in their proper historical perspective: (1) the discovery of the striatal DA deficit in the PD brain; (2) the development of the [)A replacement treatment with L-dopa, and (3) the 'birth' of the nigrostriatal DA pathway. The opposition to the new observations and their unexpected and far-reaching consequences will be illustrated by briefly discussing the strongly negative opinions expressed by some famous brain scientists of the day about the relationship between the substantia nigra, PD, and the DA-containing nigrostriatal fiber connection. Copyright (c) 2008 S. Karger AG, Basel.
引用
收藏
页码:114 / 117
页数:4
相关论文
共 50 条
  • [21] A Tango for Two: Dopamine and α-Synuclein Synergy May Explain Nigrostriatal Degeneration in Parkinson's Disease
    Chen, Vivian
    Saez-Atienzar, Sara
    MOVEMENT DISORDERS, 2018, 33 (02) : 249 - 249
  • [22] Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: Implications for Parkinson's disease and memory
    Leranth, C
    Roth, RH
    Elswoth, JD
    Naftolin, F
    Horvath, TL
    Redmond, DE
    JOURNAL OF NEUROSCIENCE, 2000, 20 (23): : 8604 - 8609
  • [23] Addicted to dopamine - the dopamine dysregulation syndrome in Parkinson's disease
    Evans, A. H.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S196 - S196
  • [24] Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease
    Caminiti, Silvia Paola
    Presotto, Luca
    Baroncini, Damiano
    Garibotto, Valentina
    Moresco, Rosa Maria
    Gianolli, Luigi
    Volonte, Maria Antonietta
    Antonini, Angelo
    Perani, Daniela
    NEUROIMAGE-CLINICAL, 2017, 14 : 734 - 740
  • [25] Nigrostriatal dopamine-independent resting-state functional networks in Parkinson's disease
    Ham, Jee Hyun
    Cha, Jungho
    Lee, Jae Jung
    Baek, Gwang-Min
    Sunwoo, Mun Kyung
    Hong, Jin Yong
    Shin, Na-Young
    Sohn, Young Ho
    Lee, Jong-Min
    Lee, Phil Hyu
    NEUROIMAGE, 2015, 119 : 296 - 304
  • [26] Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's disease
    Marchionini, Deanna M.
    Lehrmann, Elin
    Chu, Yaping
    He, Bin
    Sortwell, Caryl E.
    Becker, Kevin G.
    Kordower, Jeffrey H.
    Collier, Timothy J.
    BRAIN RESEARCH, 2007, 1147 : 77 - 88
  • [27] Parkin and Differential Susceptibility of Nigrostriatal and Tuberoinfundibular Dopamine Neurons in an MPTP Model of Parkinson's Disease
    Behrouz, B.
    Lookingland, K.
    Goudreau, J.
    CELL TRANSPLANTATION, 2009, 18 (02) : 209 - 209
  • [28] Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease?
    Herrera, Andrea
    Munoz, Patricia
    Steinbusch, Harry W. M.
    Segura-Aguilar, Juan
    ACS CHEMICAL NEUROSCIENCE, 2017, 8 (04): : 702 - 711
  • [29] Smoking, genes encoding dopamine pathway and risk for Parkinson's disease
    Gu, Zhuqin
    Feng, Xiuli
    Dong, Xiumin
    Chan, Piu
    NEUROSCIENCE LETTERS, 2010, 482 (01) : 31 - 34
  • [30] The role of tyrosine hydroxylase–dopamine pathway in Parkinson’s disease pathogenesis
    Zhi Dong Zhou
    Wuan Ting Saw
    Patrick Ghim Hoe Ho
    Zhi Wei Zhang
    Li Zeng
    Ya Yin Chang
    Alfred Xu Yang Sun
    Dong Rui Ma
    Hong Yan Wang
    Lei Zhou
    Kah Leong Lim
    Eng-King Tan
    Cellular and Molecular Life Sciences, 2022, 79